Objectives: The long-term cost effectiveness of routine HIV testing is favorable relative to other medical interventions. Facility-specific costs of expanded HIV testing and care for newly identified patients, however, are less well defined. To aid in resource allocation decisions, we developed a spreadsheet-based budget-impact tool populated with estimates of facility-specific HIV testing and care costs incurred with an expanded testing program. Methods: We modeled intervention effects on quarterly costs of antiretroviral therapy (ART), outpatient resource utilization, and staff expenditures in the Department of Veterans Affairs over a 2-year period of increasing HIV testing rates. We used HIV prevalence estimates, screening rates, counseling, positive tests, Veterans Affairs treatment, and published sources as inputs. We evaluated a single-facility cohort of 20,000 patients and at baseline assumed a serodiagnostic rate of 0.45%. Results: Expanding testing from 2% to 15% annually identified 21 additional HIV-positive patients over 2 years at a cost of approximately $290,000, more than 60% of which was due to providing ART to newly diagnosed patients. While quarterly testing costs decreased longitudinally as fewer persons required testing, quarterly ART costs increased from $10,000 to more than $60,000 over 2 years as more infected patients were identified and started on ART. In sensitivity analyses, serodiagnostic and annual HIV testing rates had the greatest cost impact. Conclusions: Expanded HIV testing costs are greatest during initial implementation and predominantly due to ART for new patients. Cost determinations of expanded HIV testing provide an important tool for managers charged with allocating resources within integrated systems providing both HIV testing and care.
Introduction
Early diagnosis of HIV infection allows for the timely initiation of highly effective, life-prolonging antiretroviral therapy (ART). The impact of early treatment and its cost-effectiveness have led the Centers for Disease Control and Prevention to recommend universal HIV testing (otherwise known as routine or non-risk-based testing) for all persons between the ages of 13 to 64 years in populations in which the prevalence of HIV infection exceeds 0.1% while others recommend offering tests to all adults [1] [2] [3] [4] [5] . Because most individuals interact routinely with primary care physicians, programs to increase universal HIV testing rates are most appropriately initiated in the primary care setting. Unfortunately, opportunities for HIV testing during routine medical care are often missed by providers, or passed over by patients. As a consequence, many HIV-positive patients are identified and diagnosed later in the disease course than is optimal [6, 7] .
While early recognition and therapy for HIV infection is costeffective for patient populations with a greater than 0.1% prevalence of undiagnosed infection, it is not costsaving. The Robert Wood Johnson Foundation [8] has expressed this distinction as follows:
''Cost-saving'' and ''cost-effective'' are distinct terms that are often mistakenly used interchangeably. Preventive care that decreases costs is cost-saving (e.g., many childhood immunizations). If the benefits are sufficiently large compared to the costs, the intervention is ''cost-effective'' even if it does not save money.
Previous studies have found that the implementation of routine, once-per lifetime HIV testing increased the lifetime cost of care for an individual HIV-infected patient by $333 to $2600 [1, 2] . Furthermore, the health benefits of routine HIV testing to identify patients with asymptomatic infection accrue over many years, while the costs of testing and managing newly identified patients arise immediately. This mismatch between the immediacy of facility-specific costs of program implementation and the delayed benefits, which may accrue after the patient has changed health care providers, can provide a disincentive for managers in health care systems with incomplete longitudinal care, as is the case in the United States, to implement HIV testing programs in the face of short-term budget time frames and competing resource demands [9] .
In this study, we estimated the facility-level budget impact of increasing HIV testing rates and providing ART to newly diagnosed patients in US Veterans Healthcare Administration (VHA) facilities. This analysis benefited from data collected during the implementation of a program to promote HIV testing in the VHA that demonstrated a sustainable doubling to tripling of HIV testing rates in primary care clinics [10, 11] . Previous budget impact analyses of the costs of implementing HIV testing programs in the United States have taken a societal perspective and excluded HIV-infected patients receiving care in the VHA [12] . This work, by contrast, focuses on the costs borne by integrated health care systems that both offer HIV testing and provide HIV care.
Methods

Construction of the Budget Impact Model
We constructed a spreadsheet-based budget impact analysis model. We estimated facility costs for HIV testing in a primary care setting, including the costs of pretest counseling, HIV testing rates and treatment of identified HIV-infected patients, (e.g., the need for increased MD full-time equivalent positions, increased pharmacy purchases of antiretroviral agents, and laboratory costs of monitoring the effectiveness of such therapy). We chose to evaluate facility costs quarterly. We did not include the costs of routine primary care or of institutional reorganization to promote HIV testing. To provide a broader context for the costs of HIV testing, we also estimated the costs of ongoing ART and monitoring for previously identified HIV-infected patients.
Data Collection
To refine the model, we solicited expert opinion from two Veterans Affairs (VA) HIV providers (an infectious disease/HIV specialist and a general internist with specific interest in HIV/ AIDS identification and care) to determine the model end points of interest. We selected the following end points: physician and nurse staffing costs, laboratory costs, and costs of ART associated with differing levels of HIV disease progression as calculated by CD4 count. The model was dynamic and considered quarter-toquarter changes in patient status (i.e., changes in CD4 þ cell count), loss to follow-up, and mortality. Figure 1 provides an overview of the flow of patients through the three phrases of HIV care: screening, diagnostics, and management. The model can be envisioned as a quarter-to-quarter flowchart designed to calculate the costs associated with both tested and untested patients of known and unknown HIV status receiving care at a single medical facility over eight 3-month periods (quarters). In our model, we assumed that primary care nurses were responsible for offering and ordering HIV tests. Baseline case variables and ranges used in the spreadsheet models are presented in Table 1 .
Model Description
We first estimated the proportion of patients (screened and unscreened for HIV) on the basis of data from our previous work [10] . We then assembled a hypothetical annual cohort of 20,000 adult patients, of whom 9.2% had previously been tested for HIV with the added assumption of a 2.1% annual baseline rate of HIV testing in previously untested patients. We assumed that 200 patients were already known to be HIV infected and were receiving care. By using the inputs shown in Table 1 , the model estimated the number of patients in each quarter who would be tested for HIV, the number who would be found to be infected, the distribution of newly diagnosed patients in different clinical strata (i.e., with 4500 CD4 þ cells/mL, with 350 to 500 CD4 þ cells/ mL, with between 200 and 350 CD4 þ cells/mL, and, finally, with fewer than 200 CD4 þ cells/mL), and the proportion of newly diagnosed patients in each stratum who started ART. The number and characteristics of newly diagnosed patients in each strata were used to calculate the quarterly costs of patient care and ART for these individuals.
Results
We first assessed the costs of maintaining a low, baseline 2.1% annual rate of HIV testing (Fig. 2) ; costs are separated into those that are related to HIV diagnostic testing and the care of persons newly identified as HIV infected versus costs related to the care of patients previously identified as being HIV infected. Our model shows that the costs of maintaining this baseline HIV testing program is a small proportion of the total costs of the HIV care program, as the mean quarterly laboratory, personnel, and pharmacy costs were $1,400 versus $33,000, $1,300 versus $61,000, and $6,404 versus $647,000 comparing the testing program with the care program for previously identified patients, respectively. Notably, pharmaceutical expenditures for ART of patients entering care accounts for 71% of the costs of the testing program. While the personnel costs for nursing involvement in primary care clinics and laboratory costs due to HIV diagnostic testing per se gradually decrease as the pool of previously untested patients diminishes over time, overall personnel, laboratory, and pharmacy costs attributed to the testing program increase as more HIV-infected patients enter care and require subspecialty clinical services, specialized laboratory monitoring, and ART.
We next assessed the costs associated with increasing the rate of HIV testing (Fig. 3) . By increasing the testing rate from a baseline of 2.1% to 15%, the model inputs predict that the facility would incur an additional cost of approximately $290,000 over a 2-year period (right panel, Fig. 3 ), of which $73,000 (25%) is attributable to the cost of testing per se (left panel, Fig. 3 ). The overall increase is largely due to pharmaceutical expenditures for ART and is thus highly sensitive to the distribution of advanced disease among newly identified patients and to the consequent rate at which ART is initiated. As shown in Figure 3 , the costs of the expanded HIV testing program per se peak at approximately $10,000 in the first quarter of program implementation. In contrast, the marginal cost of caring for newly identified patients steadily increases over time, reaching more than $50,000 in the eighth quarter of increased testing. This trend reflects increases in the aggregate number of newly diagnosed patients receiving ART. Over the course of 2 years, our base-case conditions indicate that whereas 3 patients would be newly diagnosed with a testing rate of 2.1%, 24 patients would be newly diagnosed by instituting an annual testing rate of 15%.
Sensitivity Analysis
To both evaluate the robustness of our baseline case values and to aid managers making implementation decisions, we conducted a series of sensitivity analyses based on the values listed in Table 1 . For our base case, we used values derived from studies and analyses of data from VA health care facilities [10, 13, 14] . These included a preintervention HIV testing rate of 2.1% per year, a postintervention test rate of 15% per year, a 9.2% prevalence of known prior HIV testing, a 0.45% HIV serodiagnosis rate, and 3 minutes of nursing time to explain the rationale for HIV testing, obtain verbal consent for testing, and order the test. For our sensitivity analysis, we considered the effect of separately altering each of these variables on the marginal increase in pharmacy, personnel, and laboratory costs over the 2-year period of interest.
As shown in Figure 4 , for a postintervention test rate of 30% rather than 15%, the aggregate 2-year pharmaceutical, personnel, and laboratory costs of the program increased from approximately $290,000 (base case) to $580,000. Similar large increases (to nearly $575,000) were found if the prevalence of HIV infection among tested patients was estimated to be 1.0% rather than 0.45%. As in the base-case analyses, pharmaceutical costs for ART accounted for more than 60% of all costs in all cases except when the HIV prevalence was assumed to be 0.1%, in which case pharmaceutical costs accounted for 42% of all increased expenditures. Within the examined bounds, the costs of the HIV testing program were relatively insensitive to changes in the time nurses devoted to obtaining verbal consent and ordering tests, or in the proportion of patients previously tested for HIV.
Discussion
The mismatch between the well-established delayed benefits of HIV testing and care versus the immediate costs of HIV testing and care provides a potential disincentive for investing in enhanced HIV testing programs. In this article, we performed a budget impact analysis to estimate the costs of increasing HIV testing. This provides a framework that health care managers can use in making resource allocation decisions related to HIV testing. This analysis, which used VHA-specific inputs derived in part from our previous work demonstrating the sustainable twoto threefold increase in HIV testing [10.11] , showed that an even greater increase in HIV testing, that is, from 2.1% to 15% annually, is accompanied by an initial facility-level cost of $10,000 per quarter that steadily increases to more than $60,000 per quarter 2 0 1 2 ) 1 0 2 2 -1 0 2 8 at the end of 2 years. This cost is relatively modest compared with the budget of the average VHA facility, which is well over $300 million per year. In our base-case conditions, this increase in testing would result in an additional 21 patients being identified as being HIV infected. If only the costs of HIV testing per se are considered, an enhanced HIV testing program that results in 21 additional diagnoses is predicted to cost less than $80,000 over a 2-year period. In health care systems that provide both HIV testing and HIV care, however, it is the cost of caring for these newly identified patients that accounts for more than 60% of the costs of enhanced testing. Thus, in our base case, while the cost of HIV testing was less than $80,000 over a 2-year period, the cost of ART for newly infected patients was more than $200,000. We augmented our base-case analysis by sensitivity analyses that assessed the effect of increasing the HIV testing rate from 15% to 30%, the rate of positive tests from 0.45% to 1%, and nursing time for pretest activities from 3 to 5 minutes. Because of detecting a greater number of infected patients and starting such individuals on ART, increases in the HIV testing rate from 15% to 30% or in HIV seropositivity from 0.45% to 1.0% showed a twofold cost increase ($ $300,000) compared with baseline. In contrast, changes in the time allocated for nurse-based pretest counseling or in the proportion of patients previously tested for HIV had relatively little impact on cost.
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Our findings indicate that recommendations to routinely offer HIV testing to all adults aged 13 to 64 years, as per the Centers for Disease Control and Prevention [3] , or to all adults regardless of age, as per the American College of Physicians [4] and the Veterans Health Administration [5] , is not only cost-effective using a $50,000 per quality-adjusted life-year threshold [1, 2] but also within reasonable cost bounds, with a total cost of $80,000 over 2 years for testing per se and $290,000 for testing and subsequent care of the 21 additional HIV-infected patients identified in our base-case model. As such, these results are of value to health care managers who need to plan for the additional organizational costs during the initial implementation and Fig. 2 -Cost of testing and medical care of previously identified HIV-infected patients' maintenance of 2.1% annual testing rate. The figure shows the cost of sustaining the baseline HIV testing program in which 2.1% of previously untested patients undergo HIV testing each year as well as the costs of caring for patients identified as being HIV infected prior to quarter 1. The left-hand panel includes the cost of the testing program per se as well as the costs for outpatient personnel, laboratory monitoring, and antiretroviral agents for persons newly found to be HIV infected during the eight quarters of testing. The right-hand panel provides the costs for outpatient personnel, laboratory monitoring, and antiretroviral agents previously identified as being HIV infected and receiving care. and the laboratory, personnel, and antiretroviral costs of caring for persons newly identified as being HIV infected when the annual rate of testing previously untested patients is increased from 2.1% to 15%. postintervention phases of expanded HIV testing and treatment programs [1] .
Budget impact analyses complement cost-effectiveness analyses and implementation-based trials. The latter provide necessary but not sufficient evidence for the large-scale dissemination of clinical interventions. In contrast, budget impact analyses can help inform decision makers regarding the short-term costs of implementing a specific intervention. The ability to categorize and highlight the sources of organizational costs, which many times occur across internal organizational boundaries, is crucial to convince internal stakeholders to participate in new largescale projects. Budget impact evaluations are most useful in integrated systems such as the VA, where trade-offs between internal stakeholders that involve long-term and short-term outcomes are more easily made than when the financial impacts have disparate effects on organizationally independent entities that are not as intricately bound to one another financially [12] .
In the work presented here, we followed the guidelines put forth (with some modification) by the International Society of Pharamacoeconomic and Outcomes Research Task Force. Because our core objective was to present a feasible and adaptable framework for health care managers to adopt and modify, we chose a simple-to-use spreadsheet model to perform this budget impact analysis. An important aspect of this planning tool is its flexibility, which allows for customization of inputs to accommodate different cost structures, clinical practices, and patient populations at differing VA and non-VA facilities. An alternative approach would have been to use a deterministic Markov model that considers the natural history of HIV patients, which could then be used to address budget impact analysis.
Limitations
Our analysis considers facility-specific costs over a relatively short 2-year period. This choice was purposely made because our goal was to evaluate the initial impact of implementing expanded HIV testing programs. We also assumed that the patient population remained constant over this 2-year interval whereas approximately 20% of patients enrolled in VA health care do not utilize the system in a given year [15] . To the degree that this loss to follow-up occurs for patients identified as being HIV infected, however, this would reduce the global costs of an HIV testing program by reducing ART expenditures.
Nevertheless, the 2-year analysis still informs decisions regarding the allocation of resources within integrated health care facilities that provide both HIV testing and care and complements other analyses of the long-term individual and societal costs of expanded HIV testing and earlier initiation of ART [12, 16] . In addition, although a yearly rate of HIV testing of 15% to 30% might be criticized as being low, this is similar to rates that have been considered reasonably achievable and appropriate by others [12] . Finally, while our analysis relied heavily on VAspecific data, the overall findings are likely to be relevant to other health care systems with a fixed global budgeting structure and with longitudinal patient follow-up [17] .
Conclusions
Translating clinical research into real-world improvements is a challenge for all health care systems especially when the intervention is not costsaving and the clinical benefits of the intervention are delayed. Expanded HIV testing is no exception. It has demonstrated downstream positive effects on health, but first health care systems must be transformed to provide routine testing reliably. This budget impact analysis indicates that the costs of such a program are not formidable. We found that in an integrated care system, an increase in HIV testing from 2.1% to 15% annually is accompanied by a relatively modest initial facility-level cost of $10,000 per quarter that increases to more than $60,000 per quarter at the end of 2 years because of the cost of providing ART to persons entering care for newly identified HIV infection. For programs that only offer testing to a fixed patient population, the costs of testing decrease over time as the number of untested people decreases. Fig. 4 -Aggregate increased cost over eight quarters with expansion of HIV testing under varying conditions. The base case used a prior HIV testing rate of 2.1% per year, a postintervention test rate of 15% per year, assumed that 9.2% of the patients had been previously tested for HIV infection, that 0.45% of all tests represented true positive tests, and that nurses spent 3 minutes explaining the rationale for HIV testing and obtaining verbal consent for testing to be done. Other conditions vary as indicated in the figure. ÃTotal pharmacy costs were $375,000 (off scale).
y Total pharmacy costs were $407,000 (off scale).
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